Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply
Publications
- 2023
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis:a multicentre, double-blind, placebo-controlled phase 2b study
Guttman-Yassky, E., Simpson, E. L., Reich, K., Kabashima, K., Igawa, K., Suzuki, T., Mano, H., Matsui, T., Esfandiari, E. & Furue, M., 21.01.2023, In: LANCET. 401, 10372, p. 204-214 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review